|Videos|September 2, 2022
Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy
Author(s)Sunandana Chandra, MD, MS
An overview of the treatment options for patients with mUM who ineligible for treatment with tebentafusp.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Trending on CURE
1
5 Years of Prostate Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
2
What Your Friend with Cancer REALLY Needs
3
Getting on My Ovarian Cancer Awareness Soap Box Again Because I Love My Daughter
4
FDA Grants Final Approval to OMCAZIO, a New Capsule Formulation of Cabozantinib
5